Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deciphera's Ripretinib Cuts GIST Death Risk By 64%; US Filing On Track For Early 2020

Executive Summary

Overall survival for patients with gastrointestinal stromal tumors (GIST) in the fourth-line setting was 15.1 months versus 6.6 months for placebo, building on impressive progression-free survival results.

You may also be interested in...



Deciphera’s Qinlock Hits GIST Roadblock With Phase III Failure

The drug remains likely to get approval in Europe, but for now stuck in fourth-line treatment. The company’s pipeline lacks other near-term catalysts.

FDA Approval Makes Deciphera’s Qinlock First Fourth-Line GIST Drug

Qinlock (ripretinib), approved as the US FDA rejected Blueprint Medicines’ Ayvakit (avapritinib) in the same indication, is priced on par with the rival drug cleared in January for a narrower GIST use.

Deciphera Plans Ripretinib NDA Filing For Q1 2020 On Phase III GIST Data

CEO Steve Hoerter sees best-in-class potential for the drug based on both efficacy and safety in the fourth-line gastrointestinal stromal tumor setting, with the INVICTUS trial having positive readthrough to the ongoing Phase III INTRIGUE study in second-line GIST.

Topics

Related Companies

UsernamePublicRestriction

Register

SC125950

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel